Founded in 2017, we are a $300,000 asset management fund that specializes in secondary market investments within the U.S. In the past fiscal year, we have achieved a ROI rate of 33%. Our 30-stock portfolio is mainly comprised of large- and mid-cap domestic equities in the biotech, TMT, and consumer discretionary industries.